ArQule (NASDAQ:ARQL) will be issuing its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. ArQule has set its FY 2019 guidance at $-0.39–0.37 EPS.
ArQule (NASDAQ:ARQL) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.08). ArQule had a negative net margin of 60.09% and a negative return on equity of 30.51%. The firm had revenue of $2.94 million during the quarter, compared to analyst estimates of $1.81 million. On average, analysts expect ArQule to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of ARQL opened at $6.05 on Monday. The company has a quick ratio of 7.28, a current ratio of 7.28 and a debt-to-equity ratio of 0.17. ArQule has a 12-month low of $2.23 and a 12-month high of $7.21. The stock has a market capitalization of $660.03 million, a P/E ratio of -37.81 and a beta of 2.21.
Several research analysts have weighed in on the stock. Royal Bank of Canada assumed coverage on shares of ArQule in a research note on Thursday, April 11th. They set an “outperform” rating and a $9.00 target price for the company. Zacks Investment Research raised shares of ArQule from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Thursday, January 24th. BidaskClub raised shares of ArQule from a “hold” rating to a “buy” rating in a research note on Friday, April 19th. Oppenheimer set a $8.00 target price on shares of ArQule and gave the stock a “buy” rating in a research note on Thursday, March 7th. Finally, ValuEngine lowered shares of ArQule from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $7.46.
An institutional investor recently bought a new position in ArQule stock. Dimensional Fund Advisors LP bought a new position in shares of ArQule, Inc. (NASDAQ:ARQL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,444 shares of the biotechnology company’s stock, valued at approximately $32,000. 73.11% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “ArQule (ARQL) to Release Earnings on Wednesday” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2019/04/29/arqule-arql-to-release-earnings-on-wednesday.html.
ArQule Company Profile
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Recommended Story: What are momentum indicators and what do they show?
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.